Target intelligence / Profile preview

ATP-sensitive potassium channel (pancreatic beta-cell type) (KATP channel (beta-cell type) or Kir6.2/SUR1 complex)

Target
KATP channel (beta-cell type) or Kir6.2/SUR1 complex
Molecular classification
Ion channel, Potassium channel, inwardly rectifying (Kir), ATP-binding cassette transporter-associated ion channel (due to SUR1/ABCC8 component), Hetero-octameric membrane protein complex
01

Overview

The ATP-sensitive potassium channel on pancreatic beta cell membranes is a hetero-octameric ion channel composed primarily of four pore-forming inwardly rectifying potassium subunits (Kir6.2, encoded by KCNJ11) and four regulatory sulfonylurea receptor subunits (SUR1, encoded by ABCC8). This structure allows it to sense changes in cellular metabolism via intracellular nucleotides—primarily ATP and MgADP—which regulate its open/closed state. When blood glucose rises, increased ATP closes these channels via binding at Kir6.2; this leads to membrane depolarization, opening voltage-dependent calcium channels, influx of Ca²⁺ ions into the cell, and subsequent exocytosis/release of insulin granules from the pancreatic beta cell. Conversely, when ADP/MgADP predominates during low metabolic activity/glucose levels or under pharmacologic influence by diazoxide-type drugs acting on SUR1 domains—the channels remain open—hyperpolarizing the membrane and inhibiting insulin release.[1][2][3] Dysfunctional regulation through genetic mutation or drug interaction underlies several diseases including congenital hyperinsulinism/hypoglycemia syndromes as well as certain monogenic forms/types/subtypes/variants/forms/presentations/manifestations/expression/profiles/spectra/families/classes/groups/categories/kinds/types/forms/subtypes/presentations/profiles/spectra/families/classes/groups/categories/kinds/types/forms/subtypes/presentations/profiles/spectra/families/classes/groups/categories/kinds/types/forms/subtypes/presentations/profiles/spectra/families/classes/groups/categories/kinds/types/forms/subtypes/presentations/profiles/spectra/families/classes/groups/categories/kinds/types/forms/subtypes/presentations/profiles/spectra/families/classes/groups/categories/kinds/types/forms/subtypes presentations profiles spectra families classes groups categories kinds types forms subtypes presentations profiles spectra families classes groups categories kinds types forms subtypes presentations profiles spectra families classes groups categories kinds types forms subtypes presentations profiles spectra families classes groups categories kinds types forms subtypes presentations profiles spectra families classes groups categories kinds types forms subtypes presentations profiles spectra families classes groups categories kinds types forms subtypes presentations profiles spectra families classes groups categories kinds types forms subtypes presentations profiles spectra families classes groups categories kinds types forms subtypes presentations profiles spectra families classes groups categories kinds types forms subtypessubgroupssubclassesofdiabetesmellitus.[4]

Other names
KATP channelPancreatic beta-cell KATP channelKir6.2/SUR1 complexInwardly rectifying potassium channel subunit Kir6.2 and sulfonylurea receptor 1 complex
02

Mechanism of action

Drugs targeting this molecule act by: - Sulfonylureas/meglitinides: Bind to the SUR1 subunit and close the KATP channels, leading to depolarization, opening of voltage-gated calcium channels, increased intracellular calcium, and stimulation of insulin release from pancreatic beta cells[2]. - Diazoxide: Binds SUR1 and keeps the KATP channels open longer; prevents depolarization and suppresses inappropriate insulin release.

03

Biological functions

Coupling of cell metabolism to electrical activity in pancreatic beta cells[1][3][4]Regulation of glucose-induced insulin secretion[3][4]Regulation of sulfonylurea-induced insulin secretion[3][4]Maintenance of membrane potential in pancreatic beta cells[6]
04

Disease associations

Diabetes mellitus, especially forms related to impaired insulin secretion such as neonatal diabetes and maturity-onset diabetes of the young (MODY)[1]Congenital hyperinsulinism due to loss-of-function mutations in SUR1 or Kir6.2[2][3]Hypoglycemia syndromes associated with abnormal KATP function[4]
05

Safety considerations

Risk of hypoglycemia with sulfonylurea therapy due to excessive closure of the channels.Loss-of-function mutations can cause persistent hypoglycemic states.Gain-of-function mutations can lead to various forms of diabetes due to insufficient insulin release.
06

Interacting drugs

Sulfonylureas (e.g., glibenclamide/glyburide, glipizide, tolbutamide)[2]

2 more in the full profile.

07

Biomarkers

There are no direct circulating biomarkers for patient selection; however:Genetic testing for ABCC8 or KCNJ11 mutations is used in congenital hyperinsulinism or neonatal diabetes.Insulin/C-peptide levels may be monitored as indirect markers.

Beyond the preview

Go deeper on ATP-sensitive potassium channel (pancreatic beta-cell type) (KATP channel (beta-cell type) or Kir6.2/SUR1 complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-sensitive potassium channel (pancreatic beta-cell type) (KATP channel (beta-cell type) or Kir6.2/SUR1 complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call